GLP-1
-
healthStudy: GLP-1 Drugs Don't Disrupt Esophageal Function in Diabetes
New research shows GLP-1 receptor agonists do not significantly alter esophageal motility or reflux testing in type 2 diabetes patients.
-
healthPeptide Craze Surges Beyond GLP-1s as FDA Faces Pressure to Ease Access
The peptide market is exploding amid regulatory tensions, with the FDA set to consider loosening restrictions on several peptides this summer.
-
healthRetatrutide: The New Obesity Drug That Could Spare Muscle Mass During Weight Loss
GLP-1 triple agonist retatrutide may offer significant weight loss while preserving lean muscle, according to neuroscientist Andrew Huberman.
-
healthGlobal Obesity Crisis Widens as Treatment Access Lags in Hardest-Hit Regions
New research reveals obesity rates are accelerating in developing nations while GLP-1 drugs remain concentrated in wealthier countries, highlighting a critical equity gap.
-
healthOrforglipron Pill Sustains Weight Loss After Injection Discontinuation
New trial shows oral GLP-1 orforglipron helps maintain weight loss after stopping injectable therapies tirzepatide and semaglutide.
-
healthSemaglutide Cuts Heavy Drinking in Alcohol Disorder Trial
A new trial shows semaglutide reduced heavy drinking in patients with alcohol use disorder and obesity, suggesting a new use for GLP-1 drugs.
-
healthSemaglutide Shows Promise in Boosting Motivation for Depression Patients
Study finds GLP-1 drug improves effort-based decision-making in major depressive disorder, opening new treatment avenues.
-
health6 Common Medications That May Lower Your Dementia Risk
Studies suggest flu shots, shingles vaccines, and other common drugs may reduce dementia risk. Here's what the latest research shows.